1,463 results on '"Moliterno, David"'
Search Results
502. Survival Outcomes 1 Year After Reperfusion Therapy With Either Alteplase or Reteplase for Acute Myocardial Infarction
503. Combination therapy: management of acute myocardial infarction in the new millennium
504. Pronounced Benefit of Coronary Stenting and Adjunctive Platelet Glycoprotein IIb/IIIa Inhibition in Complex Atherosclerotic Lesions
505. Achieving tissue-level perfusion in the setting of acute myocardial infarction
506. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: Rationale and design of the PARAGON B study
507. Medicaid, managed care, and the care of patients hospitalized for acute myocardial infarction
508. Predictors of death and reinfarction at 30 days after primary angioplasty: The GUSTO IIb and RAPPORT trials
509. Platelet glycoprotein IIb/IIIa receptor antagonists
510. Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER.
511. Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes.
512. QRS duration predicts death and hospitalization among patients with atrial fibrillation irrespective of heart failure: evidence from the AFFIRM study.
513. The Evolving Role of Cardiac Troponin in the Evaluation of Cardiac Disorders.
514. Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes
515. Attainment and Maintenance of Platelet Inhibition Through Standard Dosing of Abciximab in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention
516. Differences between men and women in the management of unstable angina pectoris (the Guarantee Registry)
517. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
518. Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors
519. Treatment of non–ST-segment-elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors: an emergency department perspective
520. Bedside activated partial thromboplastin time monitoring: Just a matter of time?
521. Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart Disease
522. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non–Q-wave myocardial infarctions
523. TIMI flow and surrogate end points: What you see is not always what you get
524. Acute ischemic stroke and the acute need for expansion of stroke teams and their membership.
525. Being a Great Reviewer: Remembering the “Why”
526. Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction
527. Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE registry
528. First Chronic Platelet Glycoprotein IIb/IIIa Integrin Blockade
529. Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction fn1fn1The GUSTO-I study was supported by a combined grant from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genetech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.
530. Conjunctive Use of Platelet Glycoprotein IIb/IIIa Antagonists and Thrombolytic Therapy for Acute Myocardial Infarction
531. Effects of glycoprotein IIb/IIIa blockers
532. PREDICTORS OF DUAL ANTIPLATELET THERAPY NON-ADHERENCE AFTER PCI: ONE-YEAR INSIGHTS FROM THE PARIS REGISTRY
533. FREQUENCY AND IMPACT OF SINGLE VERSUS DUAL ANTIPLATELET CESSATION ON ADVERSE CARDIAC EVENTS: RESULTS FROM THE PARIS REGISTRY
534. Another step toward resolving the contrast controversy
535. Restenosis-an open file
536. Subacute stent thrombosis: Evolving issues and current concepts
537. Coronary interventions among patients with hepatic insufficiency: Encouragement to avoid a jaundiced view.
538. Randomized, placebo-controlled study of Lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: Rationale and design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) study
539. No Association Between Plasma Lipoprotein(a) Concentrations and the Presence or Absence of Coronary Atherosclerosis in African-Americans
540. Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non–ST-Segment Elevation Acute Coronary Syndrome Patients
541. Coronary intravascular ultrasound
542. 711-4 Low Plasma Homocysteine Levels Predict Reduced Atheroma Burden in Patients Undergoing Coronary Interventions: Evidence from Intravascular Ultrasound
543. 730-3 “Directional” Coronary Atherectomy Removes Atheroma More Effectively from Concentric than Eccentric Lesions: Intravascular Ultrasound Predictors of Lesional Success
544. 935-34 Special Considerations for Diabetics Receiving Platelet IIb/IIIa Antagonists During Coronary Interventions: Results from the EPIC Trialart
545. 784-4 Older Donor Age Predicts Increased Risk for Coronary Vasculopathy in the Year Following Transplantation: Serial Examination by Intravascular Ultrasound
546. 918-21 Intravascular Ultrasound Evidence of Significant Oversizing of Angioplasty Balloons in Female Patients
547. 755-3 Improved Prognosis for Heavy Weight Patients Receiving Thrombolysis in Acute Myocardial Infarction — Bigger is Better: Results from GUSTO
548. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes
549. Influence of intranasal cocaine on plasma constituents associated with endogenous thrombosis and thrombolysis
550. Coronary-Artery Vasoconstriction Induced by Cocaine, Cigarette Smoking, or Both
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.